Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor LapatinibReport as inadecuate

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib - Download this document for free, or read online. Document in PDF available to download.

Evidence-Based Complementary and Alternative Medicine - Volume 2014 2014, Article ID 865375, 6 pages -

Research Article

Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA

Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia

University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Received 10 June 2013; Accepted 9 December 2013; Published 22 January 2014

Academic Editor: Mei Tian

Copyright © 2014 Byeongsang Oh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Despite a number of in vitro and in vivo studies reporting the efficacy of fucoidan in treating various cancers, few studies have measured the efficacy of dietary fucoidan DF in combination with cancer drugs. Thus, we examined the sensitivity of DF in combination with the EGFR-ERBB2-targeting reagent lapatinib on cancer cells. Method. We selected six EGFR-ERBB2-amplified cancer cell lines OE19, NCI-N87, OE33, ESO26, MKN7, and BT474 as an in vitro model and tested their sensitivity to DF alone and to DF in combination with the well-known EGFR-ERBB2-targeting reagent lapatinib. Result. Overall, in drug independent sensitivity test, DF alone did not significantly inhibit the growth of EGFR-ERBB2-amplified cancer cells in vitro. When DF was given in combination with lapatinib, however, it tended to synergistically inhibit cell growth in OE33 but antagonized the action of lapatinib in ESO26, NCI-N87, and OE19. Conclusion. This study suggests that DF has the potential to increase or decrease the effects of certain anticancer drugs on certain cancer cell types. Further study is needed to explore the mechanism of interaction and synergistic antitumor activity of DF in combination with chemotherapy and targeted therapy.

Author: Byeongsang Oh, Jihun Kim, Weidong Lu, and David Rosenthal



Related documents